UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
||
|
Date of Report (Date of earliest event reported)
|
|
|
||
|
(Exact name of registrant as specified in its charter)
|
|
|
|
|
||
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
|
|
||
|
(Address of principal executive offices and zip code)
|
|
(
|
||
|
(Registrant’s telephone number, including area code)
|
|
N/A
|
||
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use
the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 |
Results of Operations and Financial Condition.
|
On May 5, 2021, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three-month period ended March 31, 2021, and
certain other information. A copy of the press release is attached as Exhibit 99.1 to this report.
The information furnished pursuant to this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
The press release furnished herewith as Exhibit 99.1 contains non-GAAP financial measures. Management believes non-GAAP financial measures assist management and investors
in evaluating and comparing period-to-period results and projections in a more meaningful and consistent manner.
| Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits.
| 99.1 |
Nu Skin Enterprises’ press release dated May 5, 2021, regarding financial results for the three-month period ended March 31, 2021.
|
| 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
NU SKIN ENTERPRISES, INC.
|
||
|
(Registrant)
|
||
|
/s/ Mark H. Lawrence
|
||
|
Mark H. Lawrence
|
||
|
Chief Financial Officer
|
||
|
Date: May 5, 2021
|
||
Exhibit 99.1
FOR IMMEDIATE RELEASE
NU SKIN ENTERPRISES REPORTS RECORD FIRST-QUARTER 2021 RESULTS
Company announces first-quarter revenue growth of 31% and EPS growth of 153%,
raises annual guidance
PROVO, Utah — May 5, 2021 — Nu Skin Enterprises, Inc. (NYSE: NUS) today announced record first-quarter 2021 revenue and earnings per share.
Executive Summary
Q1 2021 vs. Prior-year Quarter
|
Revenue:
|
$677.0 million; +31%
• +6% fx impact
or $29.6 million
|
|
Earnings Per Share (EPS):
|
$0.91; +153%
|
|
Sales Leaders:
|
60,619; +22%
|
|
Customers:
|
1,517,260; +34%
|
“We are very pleased with a strong start to 2021 with our highest-ever first quarter revenue and earnings per share,” said Ritch Wood, chief executive officer. “Our
innovative beauty and wellness product initiatives powered by our social commerce business model led to 34 percent growth in our customer base over the prior year and a 22 percent increase in global sales leaders. We were recognized again by
Euromonitor as the world’s number one beauty device systems brand.* We continue to improve our geographic balance, driven by ongoing strong performance in the West, providing a more diversified and sustainable growth profile. Our
manufacturing segment also achieved record results with 69 percent year-over-year revenue growth.”
Ryan Napierski, president and CEO-elect, added, “We continue to make progress toward our vision of becoming the world’s leading beauty and wellness company powered by
our dynamic affiliate opportunity platform. We added innovative products to our portfolio with the launch of ageLOC Boost and Nutricentials Bioadaptives, and our markets are forecasting strong demand for new product innovations being introduced
in the back half of the year. These include Beauty Focus Collagen+, which is the first product in a new beauty-from-within line, and ageLOC Meta, a metabolic health supplement and our next major Pharmanex product introduction. The West markets
continue to lead out in adopting our social commerce business model with triple-digit growth. Our affiliates are leveraging this model to connect with more consumers and attract people interested in building their own socially enabled affiliate
marketing business. In the East, we grew 14 percent in Japan and modestly in Mainland China and anticipate increased adoption of our social commerce strategy and digital tools.”
|
Nu Skin Enterprises Reports Record First-quarter 2021 Results
|
Page 2
|
Q1 2021 Year-over-year Operating Results
|
Revenue:
|
$677.0 million compared to $518.0 million
• +6% fx impact
|
|
Gross Margin:
|
74.8% compared to 75.7%
• Nu Skin business was 77.8% compared to 78.1%
• Impacted by growth in manufacturing segment
|
|
Selling Expenses:
|
40.4% compared to 39.8%
• Nu Skin business was 43.4% compared to 42.0%
|
|
G&A Expenses:
|
25.1% compared to 28.9%
|
|
Operating Margin:
|
9.3% compared to 7.1%
|
|
Other Income / (Expense):
|
$1.6 million compared to ($6.2) million
|
|
Income Tax Rate:
|
26.5% compared to 35.1%
• Benefited by geographic mix
|
|
EPS:
|
$0.91 compared to $0.36
|
Stockholder Value
|
Dividend Payments:
|
$19.3 million
|
|
Stock Repurchases:
|
$50.4 million
• $275.4 million remaining in authorization
|
Q2 and Full-year 2021 Outlook
|
Q2 2021 Revenue:
|
• Approximately +5% fx impact
|
|
Q2 2021 EPS:
|
$0.97 to $1.07; +20 to 32%
|
|
2021 Revenue:
|
• Approximately +3 to 4% fx impact
|
|
2021 EPS:
|
|
Nu Skin Enterprises Reports Record First-quarter 2021 Results
|
Page 3
|
Mark Lawrence, chief financial officer, added, “During the quarter, we continued our focus on generating shareholder
value by improving operating margin through G&A optimization and leveraging our balance sheet to repurchase nearly one million shares. We continue to create synergistic value from our Rhyz manufacturing companies as they enabled the
accelerated growth throughout the West. Given the strong start to the year, as well as the positive trends we have seen in customer and sales leader growth, we are increasing our annual revenue and EPS guidance.”
About Nu Skin Enterprises, Inc.
Founded more than 35 years ago, Nu Skin Enterprises, Inc. (NSE) empowers innovative companies with sustainable solutions, opportunities, technologies and life-improving
values. The company currently focuses its efforts around innovative consumer products, product manufacturing and controlled environment agriculture technology. The NSE family of companies includes Nu Skin, which develops and distributes a
comprehensive line of premium-quality beauty and wellness solutions through a global network of sales leaders in Asia, the Americas, Europe, Africa and the Pacific; and Rhyz, our strategic investment arm that includes a collection of sustainable
manufacturing and technology innovation companies. Nu Skin Enterprises is traded on the New York Stock Exchange under the symbol “NUS.” More information is available at nuskinenterprises.com.
* Source Euromonitor International Limited; Retail Value RSP terms; all channels; 2017 to 2020. Beauty Systems are at-home Skin Care
Beauty Devices that are exclusively paired or recommended to be used with a topical consumable of the same brand. Claim verification based on Euromonitor custom research and methodology conducted January-March of 2021. Sales of at-home skin care
beauty devices includes sales of electric facial cleansers as defined in Passport database. This category does not include hair care/removal appliances, body shavers, and oral care appliances.
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended,
that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to,
statements of management’s expectations regarding the company’s performance, growth, product pipeline and product introductions, customers and sales leaders, affiliates, strategies and initiatives; projections regarding revenue, earnings per
share, foreign currency fluctuations and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,”
“expect,” “anticipate,” “project,” “outlook,” “guidance,” “plan,” “forecast,” “expand,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.
The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ
materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:
| • |
risk that epidemics, including the ongoing COVID-19 pandemic, and other crises could negatively impact our business;
|
|
Nu Skin Enterprises Reports Record First-quarter 2021 Results
|
Page 4
|
| • |
adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;
|
| • |
risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that
results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, imposition of fines, or any other adverse
actions or events;
|
| • |
any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained
basis;
|
| • |
political, legal, tax and regulatory uncertainties associated with operating in international markets, including Mainland China;
|
| • |
uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and
results;
|
| • |
risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;
|
| • |
uncertainties regarding the future financial performance of the businesses the company has acquired;
|
| • |
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory
write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
|
| • |
regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if
the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements;
|
| • |
unpredictable economic conditions and events globally, including trade policies and tariffs;
|
| • |
the company’s future tax-planning initiatives; any prospective or retrospective increases in duties on the company’s products imported into the company’s markets outside of the United
States; and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets; and
|
| • |
continued competitive pressures in the company’s markets.
|
The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated
risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no
duty to update the forward-looking statements contained in this release to reflect any change except as required by law.
Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It
is calculated by translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that
constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.
|
Nu Skin Enterprises Reports Record First-quarter 2021 Results
|
Page 5
|
The Company’s revenue results by segment for the three-month periods ended March 31 are presented in the following table (in thousands).
|
Three Months Ended
March 31,
|
Constant-
Currency
|
|||||||||||||||
|
2021
|
2020
|
Change
|
Change
|
|||||||||||||
|
Nu Skin
|
||||||||||||||||
|
Mainland China
|
$
|
149,593
|
$
|
137,696
|
9
|
%
|
1
|
%
|
||||||||
|
Americas/Pacific
|
149,465
|
74,573
|
100
|
%
|
97
|
%
|
||||||||||
|
South Korea
|
81,131
|
75,719
|
7
|
%
|
—
|
|||||||||||
|
EMEA
|
76,180
|
35,403
|
115
|
%
|
98
|
%
|
||||||||||
|
Japan
|
69,864
|
61,300
|
14
|
%
|
11
|
%
|
||||||||||
|
Southeast Asia
|
67,585
|
69,586
|
(3
|
)%
|
(5
|
)%
|
||||||||||
|
Hong Kong/Taiwan
|
36,345
|
35,827
|
1
|
%
|
(3
|
)%
|
||||||||||
|
Other
|
705
|
773
|
(9
|
)%
|
(9
|
)%
|
||||||||||
|
Total Nu Skin
|
630,868
|
490,877
|
29
|
%
|
22
|
%
|
||||||||||
|
Manufacturing
|
45,985
|
27,147
|
69
|
%
|
69
|
%
|
||||||||||
|
Grow Tech
|
173
|
4
|
4,225
|
%
|
4,225
|
%
|
||||||||||
|
Total
|
$
|
677,026
|
$
|
518,028
|
31
|
%
|
25
|
%
|
||||||||
The company’s Customers and Sales Leaders statistics by segment as of March 31, 2021 and 2020 are presented in the following table:
|
As of
March 31, 2021
|
As of
March 31, 2020
|
% Increase (Decrease)
|
||||||||||||||||||||||
|
Customers
|
Sales Leaders
|
Customers
|
Sales Leaders
|
Customers
|
Sales Leaders
|
|||||||||||||||||||
|
Mainland China
|
316,000
|
16,716
|
271,536
|
16,159
|
16
|
%
|
3
|
%
|
||||||||||||||||
|
Americas/Pacific
|
407,413
|
12,340
|
214,139
|
6,930
|
90
|
%
|
78
|
%
|
||||||||||||||||
|
South Korea
|
152,390
|
7,099
|
174,004
|
6,608
|
(12
|
)%
|
7
|
%
|
||||||||||||||||
|
EMEA
|
296,001
|
7,950
|
140,344
|
4,237
|
111
|
%
|
88
|
%
|
||||||||||||||||
|
Japan
|
126,525
|
6,131
|
119,784
|
5,635
|
6
|
%
|
9
|
%
|
||||||||||||||||
|
Southeast Asia
|
152,889
|
6,882
|
145,116
|
6,634
|
5
|
%
|
4
|
%
|
||||||||||||||||
|
Hong Kong/Taiwan
|
66,042
|
3,501
|
66,024
|
3,348
|
—
|
5
|
%
|
|||||||||||||||||
|
Total
|
1,517,260
|
60,619
|
1,130,947
|
49,551
|
34
|
%
|
22
|
%
|
||||||||||||||||
“Customers” are persons who
purchased products directly from the company during the previous three months. Our Customer numbers do not include consumers who purchase products directly from members of our sales force.
“Sales Leaders” are
independent distributors, and sales employees and independent marketers in China, who achieve certain qualification requirements.
|
Nu Skin Enterprises Reports Record First-quarter 2021 Results
|
Page 6
|
NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)
|
Three Months Ended
March 31,
|
||||||||
|
2021
|
2020
|
|||||||
|
Revenue
|
$
|
677,026
|
$
|
518,028
|
||||
|
Cost of sales
|
170,566
|
125,793
|
||||||
|
Gross profit
|
506,460
|
392,235
|
||||||
|
Operating expenses:
|
||||||||
|
Selling expenses
|
273,746
|
206,042
|
||||||
|
General and administrative expenses
|
169,801
|
149,628
|
||||||
|
Total operating expenses
|
443,547
|
355,670
|
||||||
|
Operating income
|
62,913
|
36,565
|
||||||
|
Other income (expense), net
|
1,582
|
(6,174
|
)
|
|||||
|
Income before provision for income taxes
|
64,495
|
30,391
|
||||||
|
Provision for income taxes
|
17,065
|
10,661
|
||||||
|
Net income
|
$
|
47,430
|
$
|
19,730
|
||||
|
Net income per share:
|
||||||||
|
Basic
|
$
|
0.94
|
$
|
0.36
|
||||
|
Diluted
|
$
|
0.91
|
$
|
0.36
|
||||
|
Weighted-average common shares outstanding (000s):
|
||||||||
|
Basic
|
50,706
|
55,059
|
||||||
|
Diluted
|
52,172
|
55,101
|
||||||
 |
NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)
|
|
March 31,
2021
|
December 31, 2020
|
|||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
339,099
|
$
|
402,683
|
||||
|
Current investments
|
23,615
|
21,216
|
||||||
|
Accounts receivable, net
|
60,625
|
63,370
|
||||||
|
Inventories, net
|
363,431
|
314,366
|
||||||
|
Prepaid expenses and other
|
114,118
|
101,563
|
||||||
|
Total current assets
|
900,888
|
903,198
|
||||||
|
Property and equipment, net
|
464,247
|
468,181
|
||||||
|
Operating lease right-of-use assets
|
147,129
|
155,104
|
||||||
|
Goodwill
|
202,979
|
202,979
|
||||||
|
Other intangible assets, net
|
87,135
|
89,532
|
||||||
|
Other assets
|
147,721
|
138,082
|
||||||
|
Total assets
|
$
|
1,950,099
|
$
|
1,957,076
|
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
67,083
|
$
|
66,174
|
||||
|
Accrued expenses
|
404,493
|
446,682
|
||||||
|
Current portion of long-term debt
|
90,000
|
30,000
|
||||||
|
Total current liabilities
|
561,576
|
542,856
|
||||||
|
Operating lease liabilities
|
108,237
|
112,275
|
||||||
|
Long-term debt
|
298,120
|
305,393
|
||||||
|
Other liabilities
|
110,692
|
102,281
|
||||||
|
Total liabilities
|
1,078,625
|
1,062,805
|
||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders’ equity:
|
||||||||
|
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued
|
91
|
91
|
||||||
|
Additional paid-in capital
|
579,204
|
579,801
|
||||||
|
Treasury stock, at cost – 40.4 million and 39.7 million shares
|
(1,505,076
|
)
|
(1,461,593
|
)
|
||||
|
Accumulated other comprehensive loss
|
(71,626
|
)
|
(64,768
|
)
|
||||
|
Retained earnings
|
1,868,881
|
1,840,740
|
||||||
|
Total stockholders’ equity
|
871,474
|
894,271
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
1,950,099
|
$
|
1,957,076
|
||||
# # #
CONTACTS:
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577